Abstract
Cytokine- and anticytokine-based therapies have already entered the mainstream of medical practice. Regulatory agencies continue to approve anticytokine therapies for patients with rheumatoid arthritis, and it appears highly likely that more will be approved in the near future. Cytokines also play a role in the pathogenesis of sepsis and septic shock. Two cytokines are particularly important: interleukin-1 (IL-1) and tumor necrosis factor-α (TNF-α). However, these are not the only cytokines that are involved in sepsis, and many other cytokines are likely therapeutic targets. Whether blocking other cytokines, blocking more than one cytokine, or a combination of these will reduce mortality in the septic patient is unclear at the present time. As with many new areas in science and technology, spin-offs are anticipated. From the results of current trials examining the blocking of IL-1 and TNF-α in patients with rheumatoid arthritis, it is certain that more will be learned about the role of these cytokines in sepsis.
This is a preview of subscription content, log in via an institution to check access.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
Preview
Unable to display preview. Download preview PDF.
References
Zeni, F., Freeman, B., and Natanson, C. (1997) Anti-inflammatory therapies to treat sepsis and septic shock: a reassessment. Crit. Care Med. 25, 1095–1100.
Bresnihan, B., Alvaro-Gracia, J.M., Cobby, M., Doherty, M., Domljan, Z., et al. (1998) Treatment of rheumatoid arthritis with recombinant human interleukin-1 receptor antagonist. Arthritis Rheum. 41, 2196–2204.
Lipsky, P.E., van der Heijde, D.M., St Clair, E.W., Furst, D.E., Breedveld, F.C., et al. (2000) Infliximab and methotrexate in the treatment of rheumatoid arthritis. N. Engl. J. Med. 343, 1594–1602.
Moreland, L.W., Baumgartner, S.W., Schiff, M.H., Tindall, E.A., Fleischmann, R.M., et al. (1997) Treatment of rheumatoid arthritis with a recombinant human tumor necrosis factor receptor (p75)-Fc fusion protein. N. Engl. J. Med. 337, 141–147.
Fisher, C., Jr., Agosti, J.M., Opal, S.M., Lowry, S.F., Balk, R.A., et al. (1996) Treatment of septic shock with the tumor necrosis factor receptor:Fc fusion protein. N. Engl. J. Med. 334, 1697–1702.
Takei, S., Groh, D., Bernstein, B., Shaham, B., Gallagher, K., and Reiff, A. (2001) Safety and efficacy of high dose etanercept in treatment of juvenile rheumatoid arthritis. J. Rheumatol. 28, 1677–1680.
Granowitz, E.V., Porat, R., Mier, J.W., Pribble, J.P., Stiles, D.M., Bloedow, D.C., et al. (1992) Pharmacokinetics, saftey, and immunomodulatory effects of human recombinant interleukin-1 receptor antagonist in healthy humans. Cytokine 4, 353–360.
Alhei, K., Chai, Z., Fantuzzi, G., Hasanvan, H., Malinowsky, D., Di Santo, E., et al. (1997) Hyperresponsive febrile reactions to interleukin (IL)- 1 alpha and IL-1 beta, and altered brain cytokine mRNA and serum cytokine levels, in IL1beta-deficient mice. Proc. Natl. Acad. Sci. USA 94, 2681–2686.
Peschon, J.J., Torrance, D.S., Stocking, K.L., Glaccum, M.B., Otten, C., Willis, C.R., et al. (1998) TNF receptordeficient mice reveal divergent roles for p55 and p75 in several models of inflammation. J. Immunol. 160, 943–952.
Zheng, H., Fletcher, D., Kozak, W., Jiang, M., Hofmann, K., Conn, C.C., et al. (1995) Resistance to fever induction and impaired acute-phase response in interleukin-11ß deficient mice. Immunity 3, 9–19.
Kamijo, R., Le, J., Shapiro, D., Havell, E.A., Huang, S., Aguet, M., et al. (1993) Mice that lack the interferon-gamma receptor have profoundly altered responses to infection with Bacillus Calmette-Guerin and subsequent challenge with lipopolysaccharide. J. Exp. Med. 178, 1435–1440.
Jouanguy E, Altare F, Lamhamedi S, Revy P, Emile JF, Newport M, et al. (1996) Interferon-gamma-receptor deficiency in an infant with fatal bacille Calmette—Guerin infection. N. Engl. J. Med. 335, 1956–1961.
Echtenacher, B., Falk, W., Mannel, D.N., and Krammer, P.H. (1990) Requirement of endogenous tumor necrosis factor/cachectin for recovery from experimental peritonitis. J. Immunol. 145, 3762–3766.
Steinhauser, M.L., Hogaboam, C.M., Matsukawa, A., Lukacs, N.W., Strieter, R.M., et al. (2000) Chemokine C10 promotes disease resolution and survival in an experimental model of bacterial sepsis. Infect. Immun. 68, 6108–6114.
Alexander, H.R., Doherty, G.M., Venzon, D.J., Merino, M.J., Fraker, D.L., and Norton, J.A. (1992) Recombinant interleukin-1 receptor antagonist (IL-1ra): effective therapy against gram-negative sepsis in rats. Surgery 112, 188–194.
Remick, D.G., Call, D.R., Ebong, S.J., Newcomb, D.E., Nybom, P., Nemzek, J.A., and Bolgos, G.E. (2001) Combination immunotherapy with soluble tumor necrosis factor receptors plus interleukin 1 receptor antagonist decreases sepsis mortality. Crit. Care. Med. 29, 473–481.
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 2003 Springer Science+Business Media New York
About this chapter
Cite this chapter
Dinarello, C.A. (2003). Introduction: Cytokine Biology Relevant to Infectious Diseases. In: Kotb, M., Calandra, T. (eds) Cytokines and Chemokines in Infectious Diseases Handbook. Infectious Disease. Humana Press, Totowa, NJ. https://doi.org/10.1007/978-1-59259-309-5_1
Download citation
DOI: https://doi.org/10.1007/978-1-59259-309-5_1
Publisher Name: Humana Press, Totowa, NJ
Print ISBN: 978-1-61737-247-6
Online ISBN: 978-1-59259-309-5
eBook Packages: Springer Book Archive